<?xml version='1.0' encoding='utf-8'?>
<document id="30324277"><sentence text="Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin."><entity charOffset="50-62" id="DDI-PubMed.30324277.s1.e0" text="Delafloxacin" /></sentence><sentence text="Delafloxacin has recently received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections"><entity charOffset="0-12" id="DDI-PubMed.30324277.s2.e0" text="Delafloxacin" /></sentence><sentence text=" This article provides a balanced and comprehensive systematic critique of the literature in order to provide an up-to-date summary of its clinical pharmacology" /><sentence text=" Oral delafloxacin is rapidly absorbed and exhibits comparable exposure characteristics (300 mg intravenous versus 450 mg oral) between the two formulations, allowing easy transition from intravenous to oral therapy"><entity charOffset="6-18" id="DDI-PubMed.30324277.s4.e0" text="delafloxacin" /></sentence><sentence text=" The bioavailability is high (60-70%) and absorption is not affected by food intake, although further studies are required under clinically relevant conditions" /><sentence text=" Delafloxacin is primarily excreted renally (thus requiring renal dose adjustment in the setting of renal dysfunction), but also undergoes metabolism by uridine diphosphate-glucuronosyltransferase enzymes in the formation of a conjugated metabolite"><entity charOffset="1-13" id="DDI-PubMed.30324277.s6.e0" text="Delafloxacin" /><entity charOffset="153-172" id="DDI-PubMed.30324277.s6.e1" text="uridine diphosphate" /><pair ddi="false" e1="DDI-PubMed.30324277.s6.e0" e2="DDI-PubMed.30324277.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30324277.s6.e0" e2="DDI-PubMed.30324277.s6.e1" /></sentence><sentence text=" Few drug-drug interaction studies have been identified, although more systematic characterizations in vitro and in vivo are warranted" /><sentence text=" Delafloxacin is a concentration-dependent bactericidal agent that has in vitro susceptibility for gram-positive (notably potent activity against methicillin-resistant Staphylococcus aureus), gram-negative, and anaerobic organisms"><entity charOffset="1-13" id="DDI-PubMed.30324277.s8.e0" text="Delafloxacin" /><entity charOffset="146-157" id="DDI-PubMed.30324277.s8.e1" text="methicillin" /><pair ddi="false" e1="DDI-PubMed.30324277.s8.e0" e2="DDI-PubMed.30324277.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30324277.s8.e0" e2="DDI-PubMed.30324277.s8.e1" /></sentence><sentence text=" In addition to acute bacterial skin and skin structure infections, the clinical utility of delafloxacin has also been studied in community-acquired pneumonia, acute exacerbation of chronic bronchitis, and gonorrhea, with potentially promising findings"><entity charOffset="92-104" id="DDI-PubMed.30324277.s9.e0" text="delafloxacin" /></sentence><sentence text=" Given its mild side effect profile, including an apparent lack of association with clinically important QTc prolongation, delafloxacin is generally well tolerated"><entity charOffset="123-135" id="DDI-PubMed.30324277.s10.e0" text="delafloxacin" /></sentence><sentence text="" /></document>